SGCB and pulmonary arterial hypertension: The Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) showed that sGC stimulators are well tolerated in patients with advanced systolic left ventricular dysfunction and secondary PH due to heart failure.